To accelerate breakthroughs, the Damon Runyon Foundation provides today's best young scientists with funds to pursue innovative cancer research.
- Today’s Promising Areas of Cancer Research
- What is Cancer?
- A Broken Pipeline?
A Generation of Science at Risk
- ARISE Report
Early Career Scientists and High-Risk, High Reward Research - American Academy of Arts and Sciences
- Why We’re Losing the War on Cancer (And How To Win It)
Clifton Leaf - Fortune Magazine
August 24, 2010 > Combined therapies block brain tumor recurrence
Alonzo H. Ross, PhD (Damon Runyon Fellow ‘77-‘78) of the University of Massachusetts Medical School, Worcester, discovered that combining chemotherapy (temozolomide, TMZ) with a targeted therapy that blocks Notch signaling (γ-secretase inhibitor, GSI) blocks glioblastoma brain tumor recurrence in mice. In patients, these tumors are typically treated with surgery, radiation and TMZ, but these therapies ultimately fail due to tumor recurrence. GSIs are thought to block the cancer stem cells that resist chemotherapy/radiation and allow tumor recurrence. The researchers hope to ultimately translate these findings into the clinic. This study was published in the journal Cancer Research.